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Abstract
Objective
Human Immunodeficiency Virus (HIV) and Hepatitis C virus (HCV) co-infection is recog-
nized as a major cause of morbidity and mortality among HIV-1 infected patients. Our
understanding of the impact of HIV infection on HCV specific immune responses and liver
disease outcome is limited by the heterogeneous study populations with genetically diverse
infecting viruses, varying duration of infection and anti-viral treatment.
Methods
Viral-specific immune responses in a cohort of 151 HCV mono- and HIV co-infected former
plasma donors infected with a narrow source of virus were studied. HCV and HIV specific T
cell responses were correlated with clinical data.
Results
HIV-1 accelerated liver disease progression and decreased HCV specific T cell immunity.
The magnitude of HCV specific T cell responses inversely correlated with lower HCV RNA
load and reduced liver injury as assessed by non-invasive markers of liver fibrosis. HIV co-
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infection reduced the frequency of HCV specific CD4+ T cells with no detectable effect on
CD8+ T cells or neutralizing antibody levels.
Conclusion
Our study highlights the impact of HIV co-infection on HCV specific CD4+ T cell responses
in a unique cohort of patients for both HCV and HIV and suggests a crucial role for these
cells in controlling chronic HCV replication and liver disease progression.
Introduction
HCV co-infection is recognized as a major cause of morbidity and mortality among HIV-1
infected patients [1]. HIV-1 co-infection is associated with increased HCV load and accelerated
rates of liver disease progression [2, 3]. HCV is now the leading cause of death in HIV co-
infected subjects, with end stage liver disease accounting for up to 50% of deaths [4, 5].
The importance of viral-specific T cell responses in the early control of HIV and HCV and
resolution of HCV infection are well documented [6]. Similarly viral specific T cell responses
in chronic HIV and AIDS are well studied compared to HCV. Vigorous HCV specific CD4+
and CD8+ T cell responses are detectable in acute infection and their appearance associates
with the control of viraemia [7]. The central role of T cells in defining the outcome of HCV
infection was clearly demonstrated in the chimpanzee model, where depletion of CD4+ and
CD8+ memory T cells led to viral persistence and prolonged viraemia, respectively [8, 9]. Fur-
thermore, vaccine induced multifunctional T cells associated with early control of viral replica-
tion in chimpanzees [10, 11]. However, the chimpanzee is not suitable to study the relationship
between HCV specific immune responses and disease progression or the impact of HIV co-
infection.
The role of HCV specific T cells in HIV co-infection is unclear [12, 13]. HCV specific CD8+
T cell frequencies were reported to be lower compared to HIV specific CD8+ T cell responses
in HIV/HCV co-infected patients [14]. Moreover, the same study suggested that HIV and
HCV specific CD8+ T cells have distinct phenotypes [14]. However, interpretation of immune
studies of HIV/HCV co-infected subjects can be difficult and compromised due to the hetero-
geneity of the study populations, where patients can be infected through different routes
(injecting drug users, men who have sex with men); long term drug treatment for both virus,
derive from diverse ethnicities; show different clinical stages of HIV or HCV infection and be
infected with genetically diverse viral strains.
To overcome these limitations, we studied a unique population based outbreak of HIV-1/
HCV co-infection that occurred in a rural community in central China following paid plasma
donation scheme within a narrow period between 1993 and 1995 [15]. HIV-1 and HCV trans-
mission among paid plasma donors in China are believed to have occurred as a result of con-
taminated blood collection equipment or pooled red cells being returned to donors [16]. Thus,
all subjects in our cohort (SM cohort) were infected from a narrow genetic source of HIV-1
and HCV strains circulating over a short period of time [17]. These subjects have been concur-
rently infected for over two decades and many subjects were classified as HIV-1 slow progres-
sors not requiring HAART [17]. While most of the HIV infected patients were HAART naïve
some received HAART for a short duration (less than two years at the time of last sample col-
lection date). Furthermore, HCV infected subjects were not treated with interferon or direct
acting antiviral agents. Thus, this cohort provides a unique setting to study the natural history
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of concurrent HIV-HCV co-infection and to assess the impact on viral specific immune
responses and disease progression. To our knowledge the homogeneity of this cohort and treat-
ment naïve nature for HCV are what distinguishes this study from other reports.
Materials and Methods
Study population
Samples were collected from identified former plasma donors with HCV mono-infection and
chronic HIV/HCV co-infection, living in a small village in Henan province, China. All individ-
uals provided written informed consent. A total of 151 patients were recruited into this study,
none were treated with HAART before 2007. The patients who went on HAART, received the
treatment for no more than 2 years at the time of recruitment to study. None of the patients
were treated for HCV.
Laboratory evaluations
Patients had standard laboratory assessments performed by trained research staff and clini-
cians at Beijing You’an Hospital clinical laboratories, including a complete blood cell count,
serum bio-chemical profiles, alanine aminotransferase(ALT), alkaline phosphatase(ALP)
and gamma glutamyl transferase(γ-GT) levels, CD4 cell count, and plasma HIV-RNA level.
HCV antibody testing was performed using Elecsys Anti-HCV (Roche Diagnostics GmbH,
Germany).
Viral RNA load and genotyping
HIV RNA in plasma was detected via bDNA (VERSANT HIV-1 RNA version 3.0 bDNA
Assay, Siemens Diagnostics) with a detection limit of 50 HIV-1 RNA copies/ml. HCV RNA
was measured in serum using the qualitative Roche COBAS Amplicor assay [version 2.0;
Roche Molecular Systems (Branchburg, NJ, USA) lower limit of detection 50 IU/ml]. HCV
genotypes were determined by PCR- PCR-reverse hybridization assay (Da An Gene, Guang-
zhou, China) in serum samples of all patients who are positive with HCV RNA.
Transient Elastography
Transient elastography (TE) is a non-invasive procedure that measures the velocity of the
ultrasound pulse wave that is transmitted to the liver. The velocity correlates to the liver stiff-
ness (LS), which in turn reflects the degree of fibrosis [18–20]. TE was performed with a
FibroScan1 device (EchoSens1—Paris, France) by experienced physicians. In each patient, 10
valid measurements were performed, after which a median value of LS was obtained, measured
in kilopascals (kPa). Only patients in which LS measurements by TE had a success rate (the
number of successful acquisitions/the total number of acquisitions) of at least 60%, with an
interquartile range (IQR)< 30%, were included in our study. IQR is the difference between the
75th percentile and the 25th percentile, essentially the range of the middle 50% of the data.
Synthetic peptides for T-cell analysis
A total of 479 overlapping peptides (18-mers overlapping by 10 amino acids) spanning the
complete amino acid sequence of the HCV core, p7, ARFP, E1, E2 and NS2, NS3, NS4 and NS5
protein derived from HCV-1 genotype 1b (BEI Resources) and 2a (Sigma-Aldrich Co) were
utilized. Peptides were dissolved in DMSO (Sigma, Haverhill, Suffolk, UK) at 100mg/ml and
diluted with RPMI 1640 (20 mg/ml, long-term stock stored at -80°C) before being individually
filtered and combined into 15 pools with 7–50 peptides per pool (S1 Table).
Immunity in HCVMono and HIV/HCV Co-Infection
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Ex vivo IFNγ ELISPOT assay
200,000 PBMCs with 8μg/ml peptide were used in a standard Human IFNγ ELISPOT assay as
described elsewhere [21]. To quantify antigen-specific responses, mean spots of the control
wells were subtracted from the positive wells and results expressed as SFU/106 PBMCs.
Responses were considered positive if results were at least 3 times the mean of the quadrupli-
cate negative control wells and over 25SFU/10^6 PBMCs. If background wells had more than
30SFU/10^6 PBMCs or positive control wells (phytohemagglutinin or FEC stimulation) were
negative, the assay was excluded from further analysis. The 1b and 2a HCV subtype peptides
inducing T cell response magnitude was comparable (S1 Fig). HCV subtype 1b peptides were
used in T cell response studies.
Depletion of CD8+ T and CD4+ T cells
CD8+ T and CD4+ T cells were depleted according to manufacturers’ instruction (Dynabeads
M-450; Invitrogen, Dynal, Oslo,Norway). This method has been validated and widely used
[21]. The frequency of CD8+ T cells and CD4+ T cells were all less than 1% after depletion.
The CD4+ and CD8+ dependency of individual responses were further confirmed by in-vitro
expansion of HCV antigen specific T cells and intracellular IFNγ co-staining with CD4 or
CD8 antibody.
Antibodies and multicolor Flow Cytometric analysis
The following antibodies were used. CD4 (conjugated to eFluor-450, clone OKT4, Company
eBioscience) and CD8 (conjugated to PE Cy7, clone SK1, Company BD), LIVE/DEAD cell via-
bility stain (aqua, Thermo Fisher Scientific) IFN-γ (conjugated to AF488, clone B27, BD), CD3
(conjugated to APC H7, clone SK7, company BD). Cells were stained for surface markers as
manufacturer’s instructions. Briefly, cells were washed in PBS, pelleted by centrifugation at
1500rpm for 5 minutes and the supernatant removed completely before incubating with the
pre-titrated amounts of antibodies. The cells were incubated on ice for 20 minutes and washed
with 2ml of FACS wash buffer (PBS+2%Fetal Calf Serum+0.01% sodium azide). Cells allocated
for intracellular staining were permeabilized with Perm/fix (BD, Oxford, UK) for 15 min and
washed twice with 1× perm/washing buffer (BD). Cells were then labeled with IFN-γ. Cells
were subsequently washed twice with 1× perm/washing buffer and fixed in BD cellfix (BD).
Cell events were acquired on a nine-color CyAn Cytometer (Dako, Ely, UK), and data files
were analyzed using FlowJo software. Single-color samples were run for compensation, and
fluorescence minus one (FMO) control samples were also applied to determine positive and
negative populations, as well as channel spillover. See S2 Fig for gating strategy.
Generation of Antigen-Specific T-Cell Lines and enrichment
Antigen-specific short-term T-cell lines (STLs) were generated as previously described [22].
Briefly, PBMCs were pulsed with NS3 peptide pool for 90 minutes and cultured in 96-well
plates in RPMI1640 supplemented with 10% vol/vol human AB serum (National Blood Ser-
vice). Interleukin-2 (PeproTech EC) was added to a final concentration of 200U/ml on day 3.
STLs were restimulated with peptides every 10–15 days.
For enrichment, cell line was stimulated with NS3 peptide pool for 3–4 hours followed by
labelling with human IFNγ capture kit (Miltenyi Biotec). High IFNγ producers were sorted on
a MoFlow cytometer (DakoCytomation, gating strategy see S2 Fig). Sorted IFNγ+ cells were
expanded using phytohemagglutin-treated irradiated allogeneic PBMCs and cultured with IL-2
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100U/ml, as described elsewhere [22]. IFNγ negative population from each cell line was also
sorted and expanded, as a negative control.
Antiviral activity of T cells
Enriched HCV NS3-specific CD4+ and CD8+ T cells were pulsed by peptide at a concentration
of 5ug/ml, 0.5ug/ml, 0.05ug/ml and 0.005ug/ml for 1 hour and cultured at a density of 1X106
cells/ml at 37°C, 5%CO2 for 24 hours, before collecting supernatant and storing at -80°C. Fifty
thousand (50,000) JFH-1 Huh7.5 replicon cells were plated per well of a 48-well plate and cul-
tured with 125ul of Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine
serum and 125ul of supernatant collected from peptide-pulsed T cells. HCV replication was
assessed by measuring the luciferase activity of the replicon cells after 48 hours. The suppres-
sion of HCV replication by T cells was calculated by the percentage of reduction of HCV repli-
cation at the presence of supernatant compared to the replication without supernatant.
HCV neutralizing antibody assay
HCVpp were produced as previously reported [23]. Huh-7.5 hepatoma cells (Charles Rice, The
Rockefeller University, New York, NY) were seeded in 96 well plates at 1.1x10^5 cells/ml. The
following day serum from patients not exposed to HAART was diluted 1:1000 and incubated
with HCVpp strain H77 at 37°C for 1 hour and allowed to infect target cells. Seventy-two
hours post infection, cells were lysed and luciferase activity (relative lights units [RLU]) mea-
sured to assess infectivity. The percent neutralization was determined by subtracting the mean
of an empty vector from the HCVpp value and calculated relative to uninfected patient serum.
Statistical Analysis
Factors considered in analysis included presence of HCV and/or HIV infection, past and cur-
rent HAART treatment, serum ALT, ALP, γGT, albumin:globulin ratio, HIV-RNA level, CD4+
cell count, LS, antibody mediated viral suppression, and CD8+/CD4+ responses (SFU) etc.
Mann-Whitney test was used for comparison of T cell response magnitude, virus load and liver
stiffness, and Kruskal-Wallis test followed with Dunn’s multiple comparisons test to compare
neutralisation data. Linear regression was used for comparison of T cell response magnitude
induced by 2a and 1b HCV peptides to same sample. One-way ANOVA with Bonferroni post
test correction was carried out for group mean comparisons. Statistical analysis and graphs
were analysed using Prism 6 (Graphpad software Inc.)
Ethics
This study was approved by the local ethics committee of Beijing Youan Hospital and the Uni-
versity of Oxford Tropical Ethics Committee (OXTREC 004–05).
Results
Clinical characteristics of SM Cohort
A total of 151 HCV infected subjects were recruited to our study and divided into three groups,
stratified by HIV-1 infection status: Group 1 (HCV), group 2 (HIV/HCV) and group 3 (HIVt/
HCV)). All these patients participated in a plasma donation scheme from 1993–1995 and con-
sidered were infected with a narrow genetic source of HIV-1 and HCV strains circulating over
a short period of time [17]. They have been concurrently infected over 15 years at the time of
sample collection (between 2010–2011) with HIV-1 and HCV. Each group was further classi-
fied with respect to their ongoing HCV infection (chronic [HCVc] versus resolved [HCVr])
Immunity in HCVMono and HIV/HCV Co-Infection
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and HAART treatment for less than two years (HIVt) for study purposes at the time of recruit-
ment. Demographic and clinical data is listed in Table 1. HCV genotype could not be deter-
mined in a small proportion of subjects. As expected, significantly higher CD4+ counts were
observed in HCV mono-infected (Group 1) compared to HIV co-infected persons at the time
of recruitment (Group 2 and 3) (p<0001).
Short term HAART treatment has no impact on liver disease progression
and HCV viral load
Multiple studies have demonstrated HAART could slow down the liver fibrosis in co-infected
individuals [24–26], We first compared the treatment naïve patients in SM cohort with the
patients who went on short term HAART (less than two years at the time of the last sample col-
lection). No differences were observed in liver fibrosis(Fig 1A, p = 0.9413)), ALB/GLB ratio(Fig
1B, p = 0.6883) and HCV viral load (Fig 1C, p = 0.07).
HIV infection contributes to liver disease progression and HCV load
We next noted significantly higher liver fibrosis indices (Fig 2A, p = 0.044), lower mean albu-
min to globulin ratio (Fig 2B, p = 0.0146), and higher serum gamma-GT levels (Fig 2C,
p = 0.0071) in HIV/HCV co-infected (HIV/HCVc + HIVt/HCVc) subjects compared to HCV
mono-infected subjects. For this analysis the patient groups HIV/HCVc and HIVt/HCVc were
pooled together to increase the statistical power, as short term HAART had no impact on liver
disease progression (discussed above). Importantly, these results demonstrate that HIV con-
tributes to an increased hepatic damage in patients co-infected with HCV.
We next assessed whether HCV infection modulated HIV progression by comparing the
HIV viral load and CD4+ T cell count in HAART naïve HIV/HCV co-infected patients (HIV/
HCVc vs HIV/HCVr). We observed no apparent difference between HIV viral loads (S3A Fig)
or CD4+ T cell counts (S3B Fig) in patients with chronic(HIV/HCVc) versus resolved HCV
(HIV/HCVr).
However, we found HCV viral load was significantly higher in HIV/HCV co-infected com-
pared to HCV mono-infected (Fig 2D, p = 0.0052). We evaluated whether the clinical stage of
HIV has an impact on HCV viral load by stratifying co-infected patients with respect to their
HIV viral copy number and CD4+ T cell count. Of note, we did not observe any association
between HIV load and HCV RNA levels (data not shown), however, a higher HCV viral loads
were observed in patients with low CD4+ T cell counts (Fig 2E, p = 0.0403).
A role for HCV specific T cell responses in controlling chronic HCV
replication
To test the hypothesis that HIV-1 infection diminishes the frequency of T cell responses
against HCV, we compared the total T cell responses in HCV mono-infected and HAART
naïve HIV/HCV co-infected groups by ELISPOT assay using overlapping 18mer peptide pools
spanning the entire HCV proteome. Representative examples of T cell responses to HCV pep-
tides in our ex-vivo ELISPOT assays are shown in S4 Fig. We observed a significantly higher
frequency of IFNγ producing HCV-specific responses to core (p = 0.0359), NS3 (p = 0.0183)
and NS5 (p = 0.0057) in HCV mono-infected patients compared to co-infected patients (Fig
3A). There is a tendency, although not statistically significant, towards a better HCV-specific T
cell response in patients with CD4 counts>200, suggesting that the lack of CD4+ T cell help in
co-infection likely has an impact on HCV specific Immunity (Fig 3B).
Immunity in HCVMono and HIV/HCV Co-Infection
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HIV co-infection primarily impairs HCV specific CD4+ T cell responses
To better understand the role of HIV on HCV specific adaptive immune responses we mea-
sured functional CD4+ and CD8+ T cells in a subset of HCV mono-infected and HAART naïve
HIV co-infected individuals using an IFNγ ELISPOT assay with CD4 or CD8 depletion [21]
(Fig 4A and 4B and S5 Fig). The relative proportion of CD8+ specific T cell responses from
total T cell responses were significantly higher in HIV/HCV co-infected individuals compared
to HCV mono-infected individuals (p = 0.0001 vs p = 0.5979, Fig 4A). As expected we noted
reduced CD4+ specific T cell responses in HIV co-infected patients, most likely secondary to
HIV mediated CD4+ depletion (Fig 4A and S6 Fig). To confirm the CD4+ or CD8+ dependency
of the HCV-specific responses we generated short-term T cell lines from HCVmono- and HIV
co-infected subjects. Strong CD4+ and CD8+ T cell responses were maintained after peptide
stimulation of STLs (Fig 4B). Finally, we measured the anti-viral activity of HCV-specific
CD4+ and CD8+ T cell lines in the well characterised HCV-luciferase reporter system [27].
HCV NS3 specific CD4+ and CD8+ T cells were enriched by sorting for IFNγ expressing cells
following peptide stimulation and the conditioned media harvested to measure anti-viral activ-
ity. Importantly, peptide stimulated bulk CD4+ T cells inhibited HCV replication to compara-
ble levels as CD8+ T cells (Fig 4C and 4D).
Table 1. Patient characteristics of 151 individuals infected with HCV and /or HIV. Patients in Group 1, 2 and 3 are considered infected with HIV/HCV for
over 15 years before sampling. Group HCVc was mono-infected, HCV chronic. Group HCVr was mono-infected, HCV spontaneously resolved. Group HIV/
HCVc was HIV-1+, HCV chronic, HAART naïve. Group HIV/HCVr was HIV-1+, HCV spontaneously resolved, HAART naïve. Group HIVt/HCVc was HIV-1+,
HCV chronic, HAART treated. Group HIVt/HCVr was HIV-1+, HCV spontaneously resolved, HAART naïve. ALT, Alanine transaminase; Tbil, Total bilirubin;
ALP, Alkaline phosphatase: γ-GT, gamma glutamyl transferase; VL, viral load; IU, international units; HAART, highly active anti retroviral therapy. Values rep-
resent mean ± standard deviation.
HCVmono-infected (Group 1;
n = 45)
HIV/HCV co-infected HAART
naïve (Group 2; n = 36)
HIV/HCV co-infected HAART
received (Group 3: n = 70)
ANOVA p-value
(adjusted p)$
Chronic
Group HCVc
Resolved
Group HCVr
Chronic Group
HIV/HCVc
Resolved Group
HIV/HCVr
Chronic Group
HIVt/HCVc
Resolved Group
HIVt/HCVr
Cases (N) 24 21 29 7 42 28
Gender(M/F) 10/11 11/13 14/15 4/3 27/15 13/15
Age* (y) 53.7 ±8.8 49.5±11.3 55.4±9.3 53.2±6.4 53.03±7.4 50.8±5.2
HIV genotype - - clade B clade B clade B clade B
HCV genotype of
chronically infected
patients
1b 14 - 7 - 19 -
2a 7 - 14 - 13 -
1b and 2a mix - - - - 9 -
Unknown genotype 3 - 8 - 1 -
ALT*(U/L) 58.34±54.68 25.8±17.9 62.1±70.2 38.1±43.6 53.6±57.6 27.9±15.2 3.3E-02(2.3E-01)
Tbil*(U/L) 13.12±6.4 10.2±4.0 13.6±7.1 8.4±1.9 15.8±9.7 11.4±7.1 3.4E-02(2.4E-01)
ALP* (U/L) 23.1±6.9 20.5±6.6 25.6±7.8 22.7±5.2 29.1±9.5 29.4±12.5 2.2E-03(1.5E-
02)%
γ-GT* (U/L) 57.5±87.2 38.2±24.7 116.7±210.9 27.6±7.1 123.9±141.1 91.3±98.8 7.9E-02(5.5E-01)
HCV VL*[log(IU/ml)] 6±1.3 - 6.7±0.6 - 6.7±1.2 - 1.7E-02(1.2E-01)
HIV VL*[log(copies/ml)] - - 3.0±1.1 3.5±1.5 1.9±0.5 2.2±0.9 1.3E-07(9.4E-07)
CD4+T cell count/ml* 851±441 916±349 450±311 417±111 365±243 465±257 1.9E-11(1.3E-
10)%
$ Adjusted p value with Bonferroni correction.
%p<0.05
doi:10.1371/journal.pone.0158037.t001
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Fig 1. Short term HAART has no effect on the progression of chronic liver disease in HIV/HCV Co-
infection group. A) The degree of liver fibrosis (Group HIV/HCVc (n = 21) vs Group HIVt/HCVc (n = 19) B)
ALB/GLB ratio (Group HIV/HCVc (n = 25) vs Group HIVt/HCVc (n = 43) and C)HCV virus load (Group HIV/
HCVc (n = 29) vs Group HIVt/HCVc (n = 42) were compared between subgroups of HIV/HCV co-infected
treatment naive group and HIV/HCV co-infected group that received short term HAART. The p values
calculated by Mann-Whitney U test. Data are presented as median with interquartile range.
doi:10.1371/journal.pone.0158037.g001
Immunity in HCVMono and HIV/HCV Co-Infection
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Fig 2. HIV/HCV Co-infection affects the progression of chronic liver disease. A) The progression of liver
disease was assessed by measuring the degree of liver fibrosis. The progression of liver disease in chronic
HIV/HCV co-infected patients (Group HIV/HCVc+ HIVt/HCVc (n = 40)) was faster than chronic HCVmono-
infected patients (Group HCVc (n = 12)).B) The ALB/GLB ratio was higher in Group HCVc (n = 24) than chronic
HIV/HCV co-infected patients (Group HIV/HCVc + HIVt/HCVc (n = 67)). C)Gamma GT levels were higher in
Group HIV/HCV co-infected patients (Group HIV/HCVc + HIVt/HCVc (n = 69) than HCVc (n = 24). D)HCV virus
load was lower in Group HCVc (n = 24) than chronic HIV/HCV co-infected patients (Group HIV/HCVc +HIVt/
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HIV has no effect on HCV neutralizing antibody production
Finally, we analysed the effect of HIV co-infection on HCV specific neutralizing antibody
responses in chronic and resolved infection. As expected, we observed a statistically significant
higher level of neutralization in chronic versus resolved HCV infection (Fig 4E). However, no
differences were observed between HCVmono-infected and HIV/HCV co-infected patients
(Fig 4E).
Discussion
Access to this unique HCV mono and HIV/HCV co-infected plasma donor cohort provided us
with an opportunity to study the role of HIV on HCV-specific immunity and its association
with liver disease progression. Our results provide important insights into the immunobiology
of HCV and the impact of HIV co-infection. We confirm that HIV co-infection leads to an
accelerated liver disease progression [3, 5], short treatment of HAART seemed having no effect
on liver fibrosis and HCV viral load. The mechanisms underlying this observation are likely to
be multi-factorial, the lower HCV-specific T cell responses observed in HIV co-infection as a
consequence of decreased CD4+ T cells are likely to have contributed. Indeed, we found that
the frequency of HCV specific T cell responses in particular CD4+ T cells correlated with CD4+
T cell counts. Exhaustion of HCV-specific T cells in co-infected individuals that has been
described before is another factor that is likely to have contributed [28]. Higher HCV load and
lower T cell responses were observed in patients with low CD4 counts, however, we did not
observe any significant differences using correlation analysis, which could due to insufficient
number of patients studied. Importantly, we noted an inverse association between HCV spe-
cific T cell responses and HCV load and reduced fibrosis in chronic HCV infection. This pro-
tective effect is linked to a significantly higher virus-specific T cell responses targeting the HCV
structural proteins NS3 and NS5 in HCV mono- compared to HIV co-infected patients. These
results are in line with previous reports showing stronger HCV NS3 and NS5 specific T cell
responses in subjects who had resolved HCV infection compared to chronically infected sub-
jects [29, 30].
HIV co-infection has been reported having a negative impact on HCV-specific CD8+ T
cell responses [31, 32]. We observed much greater impact on CD4+ than CD8+, but we also
observed overall tendency of lower T cell responses (both CD4+ and CD8+) in patients with
CD4<200, indicating CD8+ T cells were also affected and likely associated with lower CD4+
counts in this cohort, which agrees with previous report.
Interestingly, we found that despite their diminished frequency and function, ex-vivo
expanded HCV-specific CD4+ T cells controlled virus replication as efficiently as HCV specific
CD8+ T cells in both mono and co-infected. These results may have important implications for
immunotherapy as they suggest that CD4+ T cells can rapidly regain their antiviral activity
after in-vitro expansion without further specific interventions, such as blockade of specific
inhibitory receptors, e.g.PD-1, supporting adoptive T cell therapy.
It is worth noting that most of the co-infected subjects in the SM cohort were likely infected
first with HCV or co-infected at the same time, since epidemiological studies show blood born
HCV transmission to be at least 10 times higher than HIV [3, 33]. The presence of HCV mono
and HIV/HCV co-infected individuals but no HIV mono-infections among plasma donors in
HCVc (n = 70)). E) A higher HCV viral loads were observed in patients with low CD4+ T cell counts in HIV/HCV
Co-infection (CD4+T<200 n = 12, CD4+T>200 n = 55). The p values calculated by Mann-Whitney U test. Data
are presented as median with interquartile range.
doi:10.1371/journal.pone.0158037.g002
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Fig 3. HCV specific T cell responses are important in the control of HCV viral load and are higher in
HCVmono infected patients. A) HCV core and NS protein specific T cell responses were compared
between a sub group of HCVmono-infected (Group HCVc (n = 21) and HAART naïve HIV/HCV co-infected
patients (group HIV/HCVc (n = 24)). Median is shown.B) HCV specific T cell responses were compared
between CD4>200 and CD4<200 in HCV/HIV co-infection group (n = 60). Data are presented as median with
interquartile range. The p values calculated by Mann-Whitney U test.
doi:10.1371/journal.pone.0158037.g003
Immunity in HCVMono and HIV/HCV Co-Infection
PLOS ONE | DOI:10.1371/journal.pone.0158037 July 25, 2016 11 / 16
Fig 4. A) Reduced percentage of CD4+ specific T cell responses in HIV co-infected patients. The percentage of HCV
specific CD4+ or CD8+ T cell responses were measured in a subset of HIV/HCV co-infected (n = 14) and HCVmono-
infected (n = 7) individuals following ex-vivo stimulation of PBMC and IFNγ ELISPOT assay after CD8+ T cell depletion
(See Materials and methods and S5 Fig). The p values calculated by Mann-Whitney U test. Data are presented as
median with interquartile range.B)Representative data from HCV NS3 peptide stimulated enriched short-term T cell
lines from three patients each of HCVmono-infected (Group HCVc) and HIV/HCV co-infected (group HIV/HCVc) to
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this cohort supports the higher risk of transmission of HCV. Furthermore, the higher rate of
HCV persistence in the co-infected group may be explained by recurrent HCV infection after
HIV co-infection [3, 34]. This scenario is further supported by the individuals co-infected with
HCV 1b and 2a subtypes (Table 1).
HCV-specific T cells immune responses were detected in the majority of chronic HCV sub-
jects in the cohort, in contrast to previous reports suggesting minimal T cell responses in
chronic HCV infection [32, 35–37]. These differences may be attributable to the use of freshly
isolated PBMC for all experiments or to the use of HCV peptides spanning genotypes 1b and
2a that represent HCV strains present in our cohort [32, 35–37]. Finally, differences in host
genetic background between Chinese and western cohorts, and also the infecting virus geno-
type may account for the observed differences.
In contrast to the significant effect of HIV on CD4+ T cell responses, we failed to observe
any effect on HCV specific neutralizing antibody levels. HCV and HIV are the most genetically
diverse viruses that rapidly change their antigenic profiles, constituting a major challenge for
vaccines that elicit cross-reactive neutralizing antibodies [38]. Nevertheless, neutralizing anti-
bodies have proven to be important in controlling both HIV and HCV infection as well as the
chimpanzee model [39, 40]. HIV is known to deplete CD4+ T cells, an important regulator in B
cell activation and class switching leading to global decline in neutralising antibody [41]. Thus,
it is striking that we did not find a significant impact of HIV on HCV neutralizing antibodies.
Our results suggest that on-going HCV replication is the primary determinant maintaining
neutralizing antibody responses [42, 43].
Taken together, we found that HIV infection contributes to progressive liver disease in the
context of HCV co-infection, most likely by modulating HCV specific T cell responses in par-
ticular CD4+ T cells but not HCV specific neutralizing antibody responses. HCV specific T cell
responses targeting the non-structural proteins associate with low HCV RNA levels, further
supporting a protective role for HCV-specific T cells.
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